Chen HH, Huntley BK, Schirger JA, Cataliotti A, Burnett JC (2006)
Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure
J Am Soc Nephrol, 17 (10), 2742-7
PubMed
16928803 DOI
10.1681/ASN.2006020161Belluardo P, Cataliotti A, Bonaiuto L, Giuffrè E, Maugeri E, Noto P, Orlando G, Raspa G, Piazza B, Babuin L, Chen HH, Martin FL, McKie PM, Heublein DM, Burnett JC, Malatino LS (2006)
Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy
Am J Physiol Heart Circ Physiol, 291 (4), H1529-35
PubMed
16648193 DOI
10.1152/ajpheart.00107.2006McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, Jacobsen SJ, Redfield MM, Burnett JC (2006)
Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure
Hypertension, 47 (5), 874-80
PubMed
16585413 DOI
10.1161/01.HYP.0000216794.24161.8cChen HH, Schirger JA, Cataliotti A, Burnett JC (2006)
Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure
Eur J Heart Fail, 8 (7), 681-6
PubMed
16459135 DOI
10.1016/j.ejheart.2005.12.005Hawkridge AM, Heublein DM, Bergen HR, Cataliotti A, Burnett JC, Muddiman DC (2005)
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure
Proc Natl Acad Sci U S A, 102 (48), 17442-7
PubMed
16293687 DOI
10.1073/pnas.0508782102Martin FL, Stevens TL, Cataliotti A, Schirger JA, Borgeson DD, Redfield MM, Luchner A, Burnett JC (2005)
Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure
Kidney Int, 67 (5), 1723-30
PubMed
15840018 DOI
10.1111/j.1523-1755.2005.00269.xJames KD, Cataliotti A, Schirger JA, Plonka S, Burnett JC (2005)
Congestive heart failure: pharmacological agents and the potential of B-type natriuretic Peptide
Curr Med Chem, 12 (12), 1439-47
PubMed
15974994 DOI
10.2174/0929867054020909Chen HH, Cataliotti A, Schirger JA, Martin FL, Burnett JC (2004)
Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure
Am J Physiol Regul Integr Comp Physiol, 288 (5), R1093-7
PubMed
15627648 DOI
10.1152/ajpregu.00682.2004Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS (2004)
Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients
J Am Soc Nephrol, 15 (4), 1029-37
PubMed
15034106 DOI
10.1097/01.asn.0000117977.14912.91Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS (2004)
Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression
Kidney Int, 65 (4), 1492-8
PubMed
15086493 DOI
10.1111/j.1523-1755.2004.00530.x